{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:40Z","timestamp":1778889760067,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clml.2018.04.011","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T22:56:24Z","timestamp":1525388184000},"page":"e275-e277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Successful Use of Bortezomib\u2013Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"William D.","family":"Marrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Cruz-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-7893","authenticated-orcid":false,"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.04.011_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.04.011_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.anndiagpath.2005.07.009","article-title":"Plasmablastic lymphoma: a clinicopathologic correlation","volume":"10","author":"Folk","year":"2006","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.clml.2018.04.011_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1601-0825.2008.01493.x","article-title":"Plasmablastic lymphoma: a review","volume":"15","author":"Rafaniello Raviele","year":"2009","journal-title":"Oral Dis"},{"key":"10.1016\/j.clml.2018.04.011_bib4","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.04.011_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: not in the mouth","volume":"11","author":"Castillo","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.04.011_bib6","first-page":"1","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","author":"Dittus","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.04.011_bib7","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic cell transplantation for plasmablastic lymphoma: a review","volume":"20","author":"Al-Malki","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2018.04.011_bib8","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.","first-page":"256","article-title":"Plasmablastic lymphoma","author":"Stein","year":"2008"},{"key":"10.1016\/j.clml.2018.04.011_bib9","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1200\/JCO.2009.22.2208","article-title":"Plasmablastic lymphoma in an immunocompetent patient","volume":"27","author":"Thakral","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.04.011_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12105-010-0168-4","article-title":"Plasmablastic lymphoma involving the parotid gland","volume":"4","author":"Bishop","year":"2010","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.clml.2018.04.011_bib11","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1182\/blood.V128.22.5320.5320","article-title":"Rare case of patient with HIV related plasmablastic lymphoma presenting with bilateral parotid involvement and hypergammalobulemia","volume":"128","author":"Hansra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.04.011_bib12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/or.2015.3808","article-title":"Human immunodeficiency virus\u2013negative plasmablastic lymphoma: a comprehensive analysis of 114 cases","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clml.2018.04.011_bib13","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2016-0232-RA","article-title":"Plasmablastic lymphoma a review of clinopathological features and differential diagnosis","volume":"140","author":"Marmon","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2018.04.011_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.04.011_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428194.2015.1050666","article-title":"Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients","volume":"57","author":"Fernandez-Alvarez","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.04.011_bib16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.leukres.2011.06.023","article-title":"Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.04.011_bib17","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus\u2013positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.04.011_bib18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:39Z","timestamp":1761870699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018302180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2152265018302180"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.04.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Use of Bortezomib\u2013Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}